InvestorsHub Logo
Followers 13
Posts 436
Boards Moderated 0
Alias Born 07/28/2019

Re: Atom0aks post# 231031

Sunday, 12/01/2019 7:57:56 PM

Sunday, December 01, 2019 7:57:56 PM

Post# of 424513

The production of fish oil for use in FDA-approved drugs and dietary supplements for human consumption represents less than 1% of fish oil use.



Quote from Amarin's collateral. Thanks for sharing Atom.

Lovaza, Epadel, Vascepa and Epenova (probably a couple of minor ones) are the handful # of drug grade "fish oil" products. Except for Lovaza with $1B sales, the others are still "small" in sales. However if the new labeling is garnered, then Vascepa (and likely Epadel) sales will shot up by N fold (pick your favor number). That means N% fish oil production will go to pharmaceutical.

Calling the supply chain expert on the board - for an industry of that size, isn't a change from 1% to 2% re-allocation of raw material concerning disruption of the industry?


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News